Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Rhea-AI Summary

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported strong Q1 2025 financial results with net revenues of $11.7 million, marking a 38% increase from the previous year. The company achieved a net profit of $1.3 million, adjusted earnings of $2.4 million, and operating cash flow of $3.9 million.

Key developments include positive Phase II study results for ifetroban in Duchenne muscular dystrophy (DMD) patients, marking the first successful Phase II study targeting cardiac complications in DMD. Additionally, Cumberland's antibiotic Vibativ® received regulatory approval in China, opening access to the world's second-largest pharmaceutical market.

The company's Q1 2025 product revenue breakdown includes Kristalose® ($3.5M), Sancuso® ($2.3M), Vibativ® ($1.4M), and Caldolor® ($1.3M). Cumberland ended the quarter with $70 million in total assets and $28.7 million in shareholders' equity.

Positive

• 38% year-over-year revenue growth to $11.7 million in Q1 2025
• Net profit of $1.3 million and adjusted earnings of $2.4 million
• Strong positive cash flow from operations of $3.9 million
• Successful Phase II study results for ifetroban in DMD patients
• Vibativ® received regulatory approval in China, accessing world's second-largest pharma market

Negative

• Significant debt with $5.2 million on credit facility

Insights

Financial Analyst

Cumberland's 38% revenue growth and profitability show strong operational execution with a healthy balance sheet supporting future opportunities.

Cumberland Pharmaceuticals has delivered impressive 38% year-over-year revenue growth in Q1 2025, with total net revenues reaching $11.7 million. This robust top-line performance translated into solid profitability metrics, with net income of $1.3 million, adjusted earnings of $2.4 million ($0.16 per share), and strong cash flow from operations of $3.9 million.

The revenue diversity across their product portfolio provides multiple growth drivers, with Kristalose® leading at $3.5 million, followed by Sancuso® ($2.3 million), Vibativ® ($1.4 million), and Caldolor® ($1.3 million). These four products account for $8.5 million of the total revenue reported.

The company's financial position appears healthy with $70 million in total assets against $41.6 million in liabilities, resulting in shareholders' equity of $28.7 million. Their debt level is moderate at $5.2 million on their credit facility, representing a debt-to-equity ratio of approximately 0.18, which provides financial flexibility for their stated interest in strategic acquisitions.

The significant spread between cash flow from operations ($3.9 million) and net income ($1.3 million) suggests solid working capital management and potentially substantial non-cash expenses being added back to determine the $2.4 million in adjusted earnings reported for the quarter.

Pharmaceutical Industry Expert

Phase II DMD success and China market entry for Vibativ significantly expand Cumberland's growth potential and therapeutic impact.

Cumberland's announcement contains two significant developments beyond their financial performance. First, the positive Phase II results for ifetroban in Duchenne muscular dystrophy (DMD) patients represents a meaningful clinical milestone. This is particularly notable as they report it's the first successful Phase II study specifically targeting cardiac complications in DMD, a devastating genetic disorder with significant unmet medical needs.

The selection of these results for a late-breaking presentation at the Muscular Dystrophy Association's Clinical & Scientific Conference indicates recognition of this advancement within the scientific community. Cumberland's next steps involve further data analysis and preparation for an FDA end-of-Phase-II meeting to discuss requirements for the product's approval path.

Second, the regulatory approval of Vibativ® in China opens access to the world's second-largest pharmaceutical market, with commercial launch expected by year-end. This geographical expansion complements their diverse product portfolio that spans multiple therapeutic areas, including gastrointestinal (Kristalose®), oncology supportive care (Sancuso®), anti-infective (Vibativ®), and pain management (Caldolor®).

The multi-faceted growth strategy outlined by CEO A.J. Kazimi encompasses organic pipeline development, international expansion, and potential strategic acquisitions, creating multiple potential value drivers beyond their currently marketed products.

NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million.

Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabilities and $28.7 million of shareholders' equity.

"We are entering an exciting time for our company, as we continue to build momentum and capitalize on a range of promising opportunities," said Cumberland Pharmaceuticals CEO A.J. Kazimi. "Our optimism is driven by strong performance from our approved brands, the expansion of international partnerships, meaningful progress across our clinical development programs and the potential for strategic acquisitions."

RECENT COMPANY DEVELOPMENTS INCLUDE:

Top-Line DMD Study Results

In February 2025, Cumberland announced positive top-line results from the Phase II study evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (DMD). This marks a breakthrough for these patients, as it's the first successful Phase II study specifically targeting the cardiac complications of their condition.

These study results were selected for a late-breaking presentation in March at the Muscular Dystrophy Association's Clinical & Scientific Conference.  That platform allowed Cumberland to share the promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease.

Next steps for Cumberland's DMD program include further data analysis and completion of a full study report in preparation for an end-of-Phase-II meeting with the FDA to determine the requirements for the product's approval.

Vibativ^® Approval in China

Cumberland's potent antibiotic, Vibativ^®, received approval from the regulatory authorities in China. This provides Cumberland access to the world's second-largest pharmaceutical market. The company expects the product to launch by the end of the year.

FINANCIAL RESULTS:

Net Revenue: For first quarter of 2025, net revenues were $11.7 million and included $3.5 million for Kristalose^®, $2.3 million for Sancuso^®, $1.4 million for Vibativ^® and $1.3 million for Caldolor^®.

Operating Expenses: Total operating expenses for the quarter were $10.4 million.

Net Income: The net income for the first quarter of 2025 was approximately $1.3 million.

Adjusted Earnings: Adjusted earnings for the quarter were $2.4 million, or $0.16 per share.

Balance Sheet: At March 31, 2025, Cumberland had approximately $70 million in total assets, including $15.1 million in cash and cash equivalents. Liabilities totaled $41.6 million, including $5.2 million on the company's credit facility. Total shareholders' equity was $28.7 million on March 31, 2025.

EARNINGS REPORT CALL:

A conference call will be held today, May 06, 2025, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results.

The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. 

Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting:

https://edge.media-server.com/mmc/p/wost2na9/.

ABOUT CUMBERLAND PHARMACEUTICALS:

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) oral, a prescription laxative, for the treatment of constipation;
• Sancuso^® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com.

About Acetadote^® (acetylcysteine) Injection

Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit www.acetadote.com.

About Caldolor^® (ibuprofen) Injection

Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever.

Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.

About Kristalose^® (lactulose) Oral Solution

Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com. 

About Sancuso^® (granisetron) Transdermal System

Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.

About Vaprisol^® (conivaptan hydrochloride) Injection

Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com. 

About Vibativ^® (telavancin) for Injection

Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com.

ABOUT CUMBERLAND EMERGING TECHNOLOGIES:

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace.

CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center provides laboratory space, equipment and infrastructure for CET's activities and other early-stage life sciences ventures.

FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited)
	March 31, 2025		December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$              15,108,413		$              17,964,184
Accounts receivable, net	10,487,925		11,701,466
Inventories, net	4,098,859		3,999,995
Prepaid and other current assets	2,181,954		2,786,513
Total current assets	31,877,151		36,452,158
Non-current inventories	9,939,236		11,005,499
Property and equipment, net	298,740		277,365
Intangible assets, net	16,986,962		17,973,449
Goodwill	914,000		914,000
Operating lease right-of-use assets	7,177,490		6,176,923
Other assets	2,742,299		2,784,016
Total assets	$              69,935,878		$              75,583,410
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$              13,927,623		$              13,914,266
Operating lease current liabilities	371,094		356,508
Current portion of revolving line of credit	—		5,100,000
Other current liabilities	11,220,902		12,250,955
Total current liabilities	25,519,619		31,621,729
Revolving line of credit - long term	5,240,733		10,176,170
Operating lease non-current liabilities	4,829,054		4,939,739
Other long-term liabilities	6,005,853		6,299,795
Total liabilities	41,595,259		53,037,433
Equity:
Shareholders' equity:
Common stock—no par value; 100,000,000 shares authorized; 14,961,137 and 13,952,624 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	51,367,883		46,821,425
Accumulated deficit	(22,710,863)		(23,967,931)
Total shareholders' equity	28,657,020		22,853,494
Noncontrolling interests	(316,401)		(307,517)
Total equity	28,340,619		22,545,977
Total liabilities and equity	$              69,935,878		$              75,583,410

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited)
	Three months ended March 31,
	2025		2024
Net revenues	$                           11,713,055		$                              8,497,701
Costs and expenses:
Cost of products sold	1,425,714		1,575,542
Selling and marketing	4,231,980		4,154,588
Research and development	1,295,076		1,158,253
General and administrative	2,463,008		2,367,907
Amortization	1,005,330		1,110,661
Total costs and expenses	10,421,108		10,366,951
Operating income (loss)	1,291,947		(1,869,250)
Interest income	125,709		96,746
Interest expense	(163,802)		(118,526)
Income (loss) before income taxes	1,253,854		(1,891,030)
Income tax expense	(5,670)		(11,442)
Net income (loss)	1,248,184		(1,902,472)
Net loss (income) at subsidiary attributable to noncontrolling interests	8,884		(43,791)
Net income (loss) attributable to common shareholders	$                              1,257,068		$                            (1,946,263)
Earnings (loss) per share attributable to common shareholders
- basic	$                                        0.08		$                                      (0.14)
- diluted	$                                        0.08		$                                      (0.14)
Weighted-average shares outstanding
- basic	14,942,522		14,098,022
- diluted	15,259,824		14,098,022

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited)
	Three months ended March 31,
	2025		2024
Cash flows from operating activities:
Net income (loss)	$             1,248,184		$           (1,902,472)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense	1,031,584		1,150,685
Amortization of operating lease right-of-use assets	285,184		285,184
Share-based compensation	74,212		78,754
Increase (decrease) in non-cash contingent consideration	44,976		(230,430)
Decrease (increase) in cash surrender value of life insurance policies over premiums paid	81,182		(129,217)
Noncash interest expense	5,362		3,810
Net changes in assets and liabilities affecting operating activities:
Accounts receivable	1,213,541		(1,066,410)
Inventories, net	967,399		170,469
Other current assets and other assets	60,371		205,619
Operating lease liabilities	(219,493)		(213,825)
Accounts payable and other current liabilities	(600,043)		(645,542)
Other long-term liabilities	(293,942)		156,728
Net cash provided by (used in) operating activities	3,898,517		(2,136,647)
Cash flows from investing activities:
Additions to property and equipment	(47,630)		(41,621)
Net investment in manufacturing facility	(1,162,357)		—
Additions to intangible assets	(18,199)		(16,565)
Net cash used in investing activities	(1,228,186)		(58,186)
Cash flows from financing activities:
Proceeds from ATM offering, net	5,266,334		—
Borrowings on line of credit	—		11,000,000
Payments on line of credit	(10,035,437)		(7,700,000)
Cash settlement of contingent consideration	(511,131)		(630,701)
Payments made in connection with repurchase of common shares	(245,868)		(247,605)
Net cash provided by (used in) financing activities	(5,526,102)		2,421,694
Net increase (decrease) in cash and cash equivalents	(2,855,771)		226,861
Cash and cash equivalents at beginning of period	$          17,964,184		$          18,321,624
Cash and cash equivalents at end of period	$          15,108,413		$          18,548,485

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share (Unaudited)
		Three months ended March 31,				Three months ended March 31,
		2025		2025		2024		2024
		Earnings impact		Earnings per share impact		Earnings impact		Earnings per share impact
Net income (loss) attributable to common shareholders		$        1,257,068		$                  0.08		$      (1,946,263)		$                (0.14)
Less: Net (income) loss at subsidiary attributable to noncontrolling interests		8,884		—		(43,791)		—
Net income (loss)		1,248,184		0.08		(1,902,472)		(0.13)
Adjustments to net income (loss)
Income tax expense		5,670		—		11,442		—
Depreciation and amortization		1,031,584		0.07		1,150,685		0.08
Share-based compensation (a)		74,212		—		78,754		0.01
Interest income		(125,709)		(0.01)		(96,746)		(0.01)
Interest expense		163,802		0.01		118,526		0.01
Adjusted earnings (loss) and adjusted diluted earnings (loss) per share		$        2,397,743		$                  0.16		$         (639,811)		$                (0.05)
Diluted weighted-average common shares outstanding:				15,259,824				14,098,022

The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.

Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance.  In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities.  Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes.  Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes.  In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.

The Company defines these supplemental financial measures as follows:

• Adjusted Earnings (loss): net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. 

            (a)        Represents the share-based compensation of Cumberland.

• Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-38-revenue-growth-in-q1-2025-302447518.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What was Cumberland Pharmaceuticals (CPIX) revenue growth in Q1 2025?

Cumberland Pharmaceuticals reported a 38% revenue growth in Q1 2025, reaching net revenues of $11.7 million compared to the prior year period.

How much profit did Cumberland Pharmaceuticals (CPIX) make in Q1 2025?

Cumberland Pharmaceuticals generated a net profit of $1.3 million and adjusted earnings of $2.4 million in Q1 2025.

What are the key products driving Cumberland Pharmaceuticals' (CPIX) revenue?

Cumberland's key revenue drivers in Q1 2025 were Kristalose® ($3.5M), Sancuso® ($2.3M), Vibativ® ($1.4M), and Caldolor® ($1.3M).

What is the significance of Cumberland Pharmaceuticals' Vibativ approval in China?

Vibativ's approval in China gives Cumberland access to the world's second-largest pharmaceutical market, with product launch expected by the end of the year.

What were the results of Cumberland's Phase II DMD study?

Cumberland reported positive top-line results from the Phase II study of ifetroban in DMD patients, marking the first successful Phase II study specifically targeting cardiac complications of the condition.